Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial

The long‐acting glucagon‐like peptide‐1 receptor agonist dulaglutide acts by stimulating insulin secretion and reducing glucagon levels in a glucose‐dependent manner both in the fasting and postprandial states, resulting in reductions of both fasting glucose (FG) and postprandial glucose (PPG). In c...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgino, Francesco, Yu, Maria, Haupt, Axel, Milicevic, Zvonko, García‐Pérez, Luis‐Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852007/
https://www.ncbi.nlm.nih.gov/pubmed/31364266
http://dx.doi.org/10.1111/dom.13844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852007/
https://www.ncbi.nlm.nih.gov/pubmed/31364266
http://dx.doi.org/10.1111/dom.13844

Ejemplares similares